FTC Blocks Edwards Lifesciences' $945M JenaValve Acquisition: Pre-Commercial Antitrust, TAVR-Aortic Regurgitation Innovation Markets, and the First Court Ruling on R&D-Stage Competition in Medical Devices

Deal at a Glance

On July 23, 2024, Edwards Lifesciences Corporation (NYSE: EW) agreed to acquire JenaValve Technology, Inc. for approximately $945 million. One day earlier, Edwards had agreed to acquire JC Medical, Inc.'s U.S./North America operations for $115 million plus a $25 million investment in JC Medical's parent company. Both companies were developing transcatheter aortic valve replacement devices to treat aortic regurgitation (TAVR-AR) — a potentially fatal heart condition affecting at least 8 million Americans. At the time of the deal announcements, no TAVR-AR device had yet received FDA approval.

On August 6, 2025, the Federal Trade Commission (FTC) challenged the JenaValve acquisition. After a six-day trial, Judge Rudolph Contreras of the U.S. District Court for the District of Columbia granted the FTC's request for a preliminary injunction on January 9, 2026. Edwards announced it would not proceed with the acquisition.

This is the first time a U.S. court has blocked a medical device acquisition based on competition in a market where no products are yet commercially available. The ruling has far-reaching implications for any medical device company considering acquisitions of development-stage competitors.

Background: Aortic Regurgitation and the TAVR-AR Opportunity

The Clinical Need

Aortic regurgitation (AR) is a progressive, potentially fatal heart condition in which the aortic valve does not close properly, allowing blood to leak backward from the aorta into the left ventricle. The condition affects at least 8 million Americans and, if left untreated, leads to heart failure and death.

At the time of the FTC's challenge, the only FDA-approved treatment for aortic regurgitation was open-heart surgery to replace the aortic valve. This is a highly invasive procedure requiring cardiopulmonary bypass, extended hospitalization, and prolonged recovery. Many patients — particularly elderly patients and those with comorbidities — are not surgical candidates.

The TAVR Revolution

Transcatheter aortic valve replacement (TAVR) has transformed the treatment of aortic stenosis (AS) — a different aortic valve condition where the valve narrows rather than leaks. Since FDA approval of the first TAVR device in 2011, TAVR has become the standard of care for severe aortic stenosis, with over 100,000 procedures performed annually in the U.S. alone. Edwards Lifesciences dominates this market with its SAPIEN valve platform, competing primarily against Medtronic's Evolut platform.

The next frontier is applying TAVR technology to treat aortic regurgitation. However, TAVR-AR presents unique technical challenges:

• Anatomical complexity: AR patients typically have dilated aortic root anatomy, making device anchoring difficult
• No calcification: Unlike aortic stenosis, AR valves lack the calcium deposits that help anchor TAVR devices
• Device design requirements: TAVR-AR devices need active fixation mechanisms to stay in place without calcium
• Regulatory pathway: TAVR-AR devices require PMA approval with pivotal clinical trials

The Market Opportunity

The TAVR-AR market represents one of the largest untapped opportunities in structural heart devices:

• 8 million+ Americans with aortic regurgitation
• In March 2026, JenaValve's Trilogy became the first TAVR-AR device to receive FDA PMA approval — a milestone that validated the market
• Prior to Trilogy's approval, the only treatment option was invasive open-heart surgery
• Revenue potential of $45,000-$60,000 per procedure (valve + procedure costs)
• Multiple analysts project the TAVR-AR market could exceed $5 billion annually

Edwards' Dual Acquisition Strategy

The JC Medical Deal (July 22, 2024)

On July 22, 2024, Edwards agreed to acquire the U.S./North America operations of JC Medical, a medical device company developing the J-Valve TAVR system. Key details:

• Purchase price: $115 million plus a $25 million investment in Genesis MedTech (JC Medical's parent company)
• Below HSR threshold: The deal did not trigger a filing and waiting period under the Hart-Scott-Rodino (HSR) Act because it fell below the reporting threshold
• Closed quickly: Edwards closed the JC Medical acquisition in late July 2024
• Technology: J-Valve (now renamed SOJOURN by Edwards) — a TAVR-AR device with a unique clasp-based active fixation mechanism
• Clinical status: Edwards began enrolling patients in the JOURNEY pivotal trial in October 2024

Critically, JenaValve was not aware of Edwards' acquisition of JC Medical when it signed its own deal with Edwards the next day.

The JenaValve Deal (July 23, 2024)

On July 23, 2024, Edwards agreed to acquire JenaValve Technology for approximately $945 million. Key details:

• Technology: Trilogy Heart Valve System — a TAVR-AR device with a porcine valve and specifically designed for treating pure aortic regurgitation
• Clinical status: JenaValve had successfully completed its ALIGN-AR pivotal trial, published initial results in March 2024 and extended results for 520 additional patients in November 2025
• Clinical pipeline: Actively enrolling in JenaVAD (patients with LVADs) and ARTIST (low and intermediate risk) trials
• Regulatory pathway: Pursuing PMA approval through the ALIGN-AR pivotal trial

Why It Was Problematic

By acquiring both JC Medical and JenaValve, Edwards would have controlled the only two TAVR-AR development programs with active U.S. clinical trials. The FTC's complaint alleged that Edwards' CEO effectively described the strategy as wanting "to be the fat kid at the pie store . . . and take them both" — a colorful characterization that appeared in court filings.

The sequential timing — JC Medical one day, JenaValve the next — and the fact that the JC Medical deal fell below the HSR reporting threshold raised serious concerns about deliberate avoidance of antitrust review.

The FTC's Challenge: Innovation Competition Theory

Legal Framework

The FTC challenged the JenaValve acquisition under Section 7 of the Clayton Act, which prohibits acquisitions where "the effect of such acquisition may be substantially to lessen competition, or to tend to create a monopoly." The FTC also sought a preliminary injunction under Section 13(b) of the FTC Act to prevent the deal from closing while the administrative proceeding proceeded.

The Innovation Market Theory

The FTC's case was groundbreaking because it argued that competition existed in a market where no products had yet received FDA approval. The theory was:

1. R&D-stage competition is real: Competition between Edwards (via JC Medical) and JenaValve to develop TAVR-AR devices meaningfully shaped device design, clinical trial strategy, speed to market, and ultimately patient outcomes
2. Innovation competition drives better products: Head-to-head competition between two development programs incentivizes both companies to invest more, innovate faster, and pursue broader clinical indications
3. Eliminating competition harms patients: Combining the only two TAVR-AR programs would reduce innovation incentives, potentially slow development timelines, narrow the scope of clinical trials, and ultimately lead to higher prices and fewer treatment options
4. Pre-commercial markets are recognizable: A relevant product market can consist of products on the path to commercialization, even before regulatory approval

Precedent: Illumina/Grail

The FTC's theory built on the precedent of its successful challenge to Illumina's acquisition of Grail in 2023, where the 5th Circuit Court of Appeals affirmed the concept of a "research, development, and commercialization" market. The Edwards-JenaValve case extended this doctrine to medical devices.

The Court's Ruling

Judge Contreras' Decision

On January 9, 2026, after a six-day trial, Judge Rudolph Contreras granted the FTC's request for a preliminary injunction. The court's opinion, filed in redacted form on January 28, 2026, made several landmark findings:

1. Pre-commercial competition matters: The court recognized — for the first time in a medical device context — that competition during the R&D phase meaningfully shapes product development, clinical strategy, and patient outcomes
2. Relevant market exists without FDA approval: The court held that a relevant product market can encompass products on the path to commercialization, even before regulatory approval
3. Two-player market: Edwards (via JC Medical) and JenaValve were the only two companies with TAVR-AR devices in U.S. clinical trials, making them the only firms positioned to reach the U.S. market in the foreseeable future
4. No effective remedies offered: Edwards refused to divest JC Medical to resolve the competitive concerns, despite requests from both JenaValve and the FTC

Edwards' Response

Edwards issued a statement: "Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients." The company announced it would not proceed with the JenaValve acquisition.

Edwards raised its full-year 2026 adjusted EPS guidance to $2.90-$3.05 from earlier guidance of $2.80-$2.95, reflecting the elimination of acquisition-related costs.

Post-Ruling Update: JenaValve Achieves FDA Approval

In a striking validation of the FTC's rationale, JenaValve's Trilogy transcatheter heart valve system received FDA Premarket Approval (PMA) on March 17, 2026 — making it the first and only transcatheter device approved in the United States for symptomatic, severe aortic regurgitation. JenaValve announced the milestone on March 18, 2026, and began U.S. commercialization on April 1, 2026, with the first commercial procedures performed simultaneously at NewYork-Presbyterian/Columbia University Irving Medical Center, Cedars-Sinai Medical Center, and Piedmont Heart Institute.

The PMA approval (P250024) was supported by the ALIGN-AR pivotal trial data. Had the Edwards acquisition been allowed to proceed, this independent competitive milestone — and the first-mover advantage that came with it — might never have occurred, or would have been significantly delayed.

The approval underscores why the FTC's intervention mattered: preserving independent competition in the TAVR-AR space led directly to faster patient access to a life-saving treatment, exactly as the agency predicted.

The TAVR-AR Competitive Landscape (Updated May 2026)

Edwards / JC Medical (SOJOURN Valve)

Edwards retains JC Medical and continues development of the SOJOURN (formerly J-Valve) TAVR-AR device:

• Pivotal trial: JOURNEY trial actively enrolling patients
• Technology: Clasp-based active fixation mechanism designed for AR anatomy
• Advantages: Edwards' massive commercial infrastructure in structural heart, established TAVR physician relationships, and deep clinical trial expertise
• Timeline: Edwards anticipated FDA approval timeline not publicly disclosed, but pivotal trial enrollment is ongoing

JenaValve (Trilogy Valve) — FDA Approved

JenaValve remains independent and has achieved a major milestone:

• FDA PMA Approval: Received on March 17, 2026 (P250024) — the first and only transcatheter device approved for symptomatic, severe aortic regurgitation in the U.S.
• ALIGN-AR pivotal trial: Successfully completed with results published in The Lancet (700 high-risk patients with moderate to severe aortic regurgitation; 95% technical success rate; 7.7% all-cause mortality at one year, well below the 25% performance goal benchmark)
• U.S. commercial launch: Began April 1, 2026, with first commercial procedures at three major medical centers
• Additional trials: JenaVAD (LVAD patients) and ARTIST (low/intermediate risk) actively enrolling to expand the addressable patient population
• First-mover advantage: As the first approved TAVR-AR device, JenaValve has a significant head start in establishing clinical adoption, physician training, and market share
• Strategic position: As an independent company with FDA-approved technology and active commercialization, JenaValve becomes an even more attractive acquisition target for other structural heart players (e.g., J&J/Abiomed, Boston Scientific, Medtronic)

Potential New Entrants

The FTC's ruling preserves the possibility of additional TAVR-AR competition:

• Medtronic: Has TAVR expertise with Evolut platform and could develop or acquire TAVR-AR technology
• Boston Scientific: Active in structural heart with multiple acquisitions and could enter TAVR-AR
• Abbott: Has portico and other TAVR platforms and structural heart capabilities
• J&J (Abiomed): Completed $16B Abiomed acquisition and has expressed interest in structural heart expansion

Implications for Medical Device M&A

1. Pre-Commercial Acquisition Scrutiny

The Edwards-JenaValve ruling establishes that the FTC will scrutinize acquisitions of development-stage competitors, even when no commercial market yet exists. Medical device companies pursuing acquisitions of clinical-stage targets should:

• Assess whether the target competes with any of the acquirer's existing or pipeline products
• Evaluate whether the acquisition would reduce the number of competitors below a competitive threshold
• Consider whether the deal structure (sequential acquisitions, sub-HSR thresholds) could raise red flags
• Be prepared to offer divestiture remedies if the FTC identifies competitive concerns

2. Below-Threshold Acquisitions Are Not Safe

The JC Medical deal ($115 million) fell below the HSR reporting threshold, meaning it was not subject to mandatory antitrust review. However, the FTC used the JC Medical acquisition as a key element in its challenge to the JenaValve deal. This signals that:

• Companies cannot avoid antitrust scrutiny by structuring deals below HSR thresholds
• Sequential acquisitions that collectively reduce competition can be challenged even if each individual deal is below the reporting threshold
• The FTC is actively monitoring the medical device M&A landscape for problematic patterns

3. Innovation Market Doctrine Is Now Established

The court's acceptance of the innovation market theory means that:

• Competition in R&D and clinical development is legally cognizable under antitrust law
• The FTC can challenge deals based on reduced innovation incentives, not just price effects
• Companies acquiring pipeline competitors face a higher bar than acquisitions of companies in unrelated therapeutic areas
• The burden of proof includes demonstrating that the acquisition will not harm innovation competition

4. Divestiture Refusal Is Risky

Edwards' refusal to divest JC Medical — despite requests from both JenaValve and the FTC — was a significant factor in the court's decision. The court noted that Edwards was "adamant in its refusal to contemplate divesting JC Medical" despite having described the JC Medical acquisition as "immaterial." This suggests that:

• Companies should be prepared to offer meaningful divestiture remedies when the FTC identifies competitive concerns
• Refusing to divest assets that the company itself characterizes as immaterial weakens the company's legal position
• The FTC views refusal to negotiate remedies as evidence of anti-competitive intent

The Regulatory Pathway for TAVR-AR Devices

Understanding the FDA regulatory pathway for TAVR-AR devices helps contextualize why the competitive dynamics matter:

PMA Pathway Requirements

TAVR-AR devices are Class III medical devices requiring Premarket Approval (PMA) from the FDA:

• Pivotal clinical trial: Required to demonstrate reasonable assurance of safety and effectiveness
• Panel review: Typically reviewed by the FDA's Circulatory System Devices Panel
• Post-approval study: Likely required as a condition of approval
• Timeline: PMA review typically takes 180-360 days after submission, but the total timeline from trial initiation to approval can span 3-5+ years

Why Competition Matters in Development

With two companies competing to develop TAVR-AR devices:

• Both invest more in clinical trial enrollment, physician training, and patient recruitment
• Each pursues broader clinical indications (high-risk, intermediate-risk, low-risk patients)
• Clinical trial designs are more rigorous as each company tries to demonstrate superiority
• Speed to FDA approval is faster because both programs are running in parallel
• Patients have access to multiple treatment options with different design philosophies

With only one company controlling both programs:

• Investment incentives may decrease without competitive pressure
• Clinical trial scope may narrow to the minimum required for approval
• Speed to market may slow without the urgency of a competing program
• Patients would ultimately have fewer device options

Key Takeaways

1. Landmark ruling: This is the first U.S. court decision blocking a medical device acquisition based on competition in a pre-commercial market, establishing the innovation market doctrine in the medical device sector.

2. Sequential acquisitions are under scrutiny: Edwards' one-two acquisition of JC Medical and JenaValve over two days — with the first deal below the HSR threshold — became the core of the FTC's case.

3. TAVR-AR is no longer pre-commercial: JenaValve received FDA PMA approval for the Trilogy system on March 17, 2026, and began U.S. commercialization on April 1, 2026 — making it the first approved TAVR-AR device. Edwards (SOJOURN/J-Valve via JC Medical) continues as an independent competitor in the TAVR-AR market.

4. Precedent for future deals: The ruling provides a legal framework for the FTC to challenge future acquisitions of development-stage medical device companies, particularly in concentrated therapeutic areas with few competitors.

5. JenaValve is now the first-mover: As an independent company with FDA-approved technology and active U.S. commercialization, JenaValve has a significant first-mover advantage and becomes an even more attractive acquisition target for other structural heart players (Medtronic, Boston Scientific, J&J/Abiomed, Abbott).

6. Divestiture is the safest remedy: Edwards' refusal to divest JC Medical — a deal it called "immaterial" — undermined its position. Companies facing FTC challenges should seriously consider divestiture as a practical remedy.

Last updated: May 29, 2026